Imaging and uptake mechanism of 131I-meta-iodobenzylguanidine in medullary thyroid carcinoma.
131I-meta-iodobenzylguanidine (131I-MIBG) was also taken up by medullary thyroid carcinoma (MTC) as well as by pheochromocytoma in two patients with Sipple's syndrome. However, the mechanism of 131I-MIBG uptake by MTC has not been clarified yet. We measured tissue catecholamine levels in three MTC, since MTC can produce several active substances. Catecholamines were detected in various amounts in all MTC, but not in normal thyroid tissues. These findings suggest that MTC can produce catecholamines and therefore, 131I-MIBG is taken up and stored in catecholamine vesicles of MTC, like pheochromocytoma and neuroblastoma. We conclude that 131I-MIBG may be applied not only to diagnosis but also for the treatment of patients with MTC.
D019797:3-Iodobenzylguanidine; D002277:Carcinoma / Q000000981:diagnostic imaging*; D004837:Epinephrine / Q000378:metabolism; D005260:Female; D006801:Humans; D007462:Iodobenzenes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009377:Multiple Endocrine Neoplasia / Q000000981:diagnostic imaging*; D009638:Norepinephrine / Q000378:metabolism; D011877:Radionuclide Imaging; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism
D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine; D009638:Norepinephrine; D004837:Epinephrine